D. Western Therapeutics Institute (TSE:4576) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
D. Western Therapeutics Institute EBITDA Margin % Related Terms
D. Western Therapeutics Institute EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute EBITDA Margin % Chart
TSE:4576 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, D. Western Therapeutics Institute's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute (TSE:4576) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on D. Western Therapeutics Institute and its competitors. According to the industry distribution chart, D. Western Therapeutics Institute ranks #639 out of 944 companies in the Biotechnology industry, placing it in the top 67.7%.
Is D. Western Therapeutics Institute's EBITDA Margin % too high?
D. Western Therapeutics Institute's current EBITDA Margin % is 0.00%. Based on the distribution chart, D. Western Therapeutics Institute ranks #639 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, D. Western Therapeutics Institute has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #639 out of 944 companies for EBITDA Margin %. This places D. Western Therapeutics Institute in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Fairly Valued. The stock's GF Value™ is 円64.35, compared to a current price of 円69.00 — trading 7.2% above its estimated fair value. The current EBITDA Margin % is 0.00%. D. Western Therapeutics Institute's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of 円69.00 is trading 7.2% above its estimated GF Value™ of 円64.35.
GuruFocus considers D. Western Therapeutics Institute to be Fairly Valued.
Key valuation signals for TSE:4576:
EBITDA Margin %: 0.00%
GF Value™: 円64.35 vs. price of 円69.00 (7.2% above fair value)
No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Business Description
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
51GF Score
Get the complete analysis for TSE:4576
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4576 has been successfully added to your 
